Many Americans were forced to postpone cancer screenings — colonoscopies, mammograms and lung scans — for several months in 2020 as COVID-19 overwhelmed doctors and hospitals.
But that delay in screening isn’t making a huge impact on cancer statistics, at least none that can be seen yet by experts who track the data.
Cancer death rates continue to decline, and there weren’t huge shifts in late diagnoses, according to a new report published Monday in the journal Cancer. It’s the broadest-yet analysis of the pandemic’s effect on U.S. cancer data.
In 2020, as the pandemic began, a greater share of U.S. cancers were caught at later stages, when they’re harder to treat. But in 2021, these worrisome diagnoses returned to prepandemic levels for most types of cancer.
“It is very reassuring,” said lead author Recinda Sherman of the North American Association of Central Cancer Registries. “So far, we haven’t seen an excess of late-stage diagnoses,” which makes it unlikely that there will be higher cancer death rates tied to the pandemic.
